Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28052660 | 0.90 | LMNA (0.37) | SLC1A3SLC1A2SLC1A1LMNACHRM3 | |
| SCHEMBL19335252 | 0.81 | CNR2 (0.34) | LMNACHRM3CNR2 | |
| SCHEMBL10150825 | 0.81 | LMNA (0.50) | SLC1A3SLC1A2SLC1A1LMNAPARP15 | |
| SCHEMBL2633967 | 0.76 | PARP15 (0.38) | SLC1A3SLC1A2SLC1A1LMNAPARP15 | |
| SCHEMBL2633968 | 0.76 | PARP15 (0.38) | SLC1A3SLC1A2SLC1A1LMNAPARP15 | |
| SCHEMBL28559151 | 0.76 | PARP15 (0.38) | SLC1A3SLC1A2SLC1A1LMNAPARP15 | |
| SCHEMBL6750673 | 0.76 | TLR4 (0.38) | LMNACNR2 | |
| SCHEMBL18314296 | 0.76 | ALDH1A1 (0.47) | CNR2 | |
| SCHEMBL28945304 | 0.76 | TP53 (0.37) | LMNA | |
| SCHEMBL28416750 | 0.76 | EPHX1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008042-A | Substituted pyrrolo [2,3-b ] pyridine and pyrazolo [3,4-b ] pyridine derivatives as protein kinase inhibitors | 重庆复创医药研究有限公司 | 2022-02-01 | — | — | CN | disclosed |